MyopathyNCT06837467
Differential SERCA Expression in Laryngeal Muscles
A study testing Immunohistochemistry (IHC) in people with Myopathy, run by Sohag University at 1 site in Egypt.
Trial summary
Immuno-localization of SERCA and MHC isoform (SERCA1, SERCA2, MHC I, and MHCII) expression and co-expression in the five ILMs were investigated in both young and aged rats with immunohistochemistry. Special concern has been placed to the denervation effect on ILMS. Read more about this study
- Who is it for?
- Ages 8 to 24 weeks, men only
- Conditions the study is for
- Myopathy
- What is being tested?
- Immunohistochemistry (IHC)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteEgypt
- Study dates
- 25 Jan 2024to 1 Feb 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 8 to 24 weeks
- Men only
- No healthy volunteers
- Child
Who may be able to join
- 8-12 weeks of age, weighing 280-350 g (N=10) were used as young rats. In addition, 24-month-old rats (N=10) were employed as aged models.
Who cannot join
- -
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Differential Expression of SERCA and Myosin Heavy Chain Isoforms in Rat Laryngeal Muscles
Immuno-localization of SERCA and MHC isoform (SERCA1, SERCA2, MHC I, and MHCII) expression and co-expression in the five ILMs were investigated in both young and aged rats with immunohistochemistry. Special concern has been placed to the denervation effect on ILMS.
Read the detailed description
Animals In this study, male adult Wistar rats (Shimizu Laboratory Supplies Co., Kyoto, Japan), 8-12 weeks of age, weighing 280-350 g (N=10) were used as young rats. In addition, 24-month-old rats (N=10) were employed as aged models.
Animal tissue preparation Animals were anesthetized with an intraperitoneal injection of sodium pentobarbital (dose 30-60 mg/kg) and were fixed with 4% paraformaldehyde following cardiac perfusion with 0.01 M phosphate-buffered saline (PBS). The larynges were excised immediately and immersed in the same fixative for approximately 12 hours at (4°C). Tissues were processed in paraffin and sectioned using a microtome (8-10 μm thickness).
The intrinsic laryngeal muscles studied were: 1) medial and lateral thyroarytenoid (MTA, LTA), (2) lateral cricoarytenoid (LCA), (3) Superior cricoarytenoid (SCA), (4) posterior cricoarytenoid (PCA), and (5) cricothyroid (CT).
Immunohistochemistry (IHC) The investigators faced unsuccessful fast fiber type identification on frozen sections then we shifted to paraffin sections. Deparaffinized sections were incubated with 3% H2O2 in PBS for 10 minutes followed by microwave treatment (5 minutes ×3 times at 500 Watt in citrate buffer, pH 6). Then, sections were incubated in a blocking solution (0.3 M glycine, 50 mM ammonium chloride, and 1% BSA in PBS) for 30 minutes before incubation in primary antibodies. Sections were incubated with anti-SERCA1 or -SERCA2 and anti-MHC I or -MHCII (Table 1) antibodies for 1-2 days at 4 ◦C, then washed, and incubated with Alexa Fluor® 488 donkey anti-mouse IgG and Fluor® 594 donkey anti-goat IgG secondary Abs for 1 hour at room temperature. Double IHC was performed using (anti-SERCA1 + anti-SERCA2) and (anti-SERCA2 + anti-MHCII) combinations to check co-expression. In double IHC, the same steps were done with a mixture of primary or secondary antibodies with the same dilutions.
Immunostained tissue sections were examined using a FV-1000 laser confocal microscope (Olympus, Tokyo, Japan). ImageJ 1.46 software was used to manually count and calculate the percentage of positive cells for each antibody.
Immunohistochemistry for denervated rat In 8-12 weeks, aged rats, the larynx was approached through a midline incision using a standard operating microscope under anesthesia with sodium pentobarbital. After identification of the right recurrent and superior laryngeal nerves, a 1 cm segment was removed from the right recurrent laryngeal nerve and both ends were ligated. The right superior laryngeal nerve was also divided. The denervated rat groups were sacrificed after 2, 4, 8, and 12 weeks. The larynx was collected and prepared for IHC using the same procedure described above (n = 5 in each group).
MHC subtypes using multi-color fiber typing:
At the beginning of our research, we tried the frozen section. After trials of several techniques to decrease autofluorescence and background noise, the investigators failed to have good staining. Then, the investigators discontinued MHC subtyping and shifted to paraffin-embedded blocks Statistical analysis The relative SERCA and MHC composition for each muscle was calculated. The available data for the positive cell percentage of each rat antibody were statistically analyzed using SPSS statistical software, version 16. Statistical comparisons were performed using the unpaired two-tailed Student's t-test and were considered significant at P < 0.05.
One-way analysis of variance (ANOVA) followed by Scheffe's post hoc test was performed to compare the MHC and SERCA composition for each muscle in denervation with the contralateral side and young with age. Values presented are means ± SD (standard deviation), with SD being across rats.
- Conditions
- Myopathy
- Being tested
- Immunohistochemistry (IHC)
- Keywords
- SERCA and MHC isoform
- Medical subject headings
- Muscular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Immunohistochemistry (IHC)Diagnostic test
We faced unsuccessful fast fiber type's identification on frozen sections then we shifted to paraffin sections. Deparaffinized sections were incubated with 3% H2O2 in PBS for 10 minutes followed by microwave treatment (5 minutes ×3 times at 500 Watt in citrate buffer, pH 6). Then, sections were incubated in blocking solution (0.3 M glycine, 50 mM ammonium chloride, and 1% BSA in PBS) for 30 minutes before incubation in primary antibodies. Sections were incubated with anti-SERCA1 or -SERCA2 and anti-MHC I or -MHCII (Table 1) antibodies for 1-2 days at 4 ◦C, then washed, and incubated with Alexa Fluor® 488 donkey anti-mouse IgG and Fluor® 594 donkey anti-goat IgG secondary Abs for 1 hour at room temperature. Double IHC was performed using (anti-SERCA1 + anti-SERCA2) and (anti-SERCA2 + anti-MHCII) combinations to check co-expression. In double IHC, the same steps were done as before with mixture of primary or secondary antibodies with same dilutions.
| Study group | Role | What they receive |
|---|---|---|
| Young rat | Experimental | male adult Wistar rats (Shimizu Laboratory Supplies Co., Kyoto, Japan), 8-12 weeks of age, weighing 280-350 g (N=10) were used as young rats Immunohistochemistry (IHC) with anti-SERCA1 or -SERCA2 and anti-MHC I or -MHCII (Table 1) antibodies for 1-2 days at 4 ◦C, then washed and incubated with Alexa Fluor® 488 donkey anti-mouse IgG and Fluor® 594 donkey anti-goat IgG secondary Abs for 1 hour at room temperature. Double IHC was performed using (anti-SERCA1 + anti-SERCA2) and (anti-SERCA2 + anti-MHCII) combinations to check co-expression. In double IHC, the same steps were done as before with mixture of primary or secondary antibodies with same dilutions. Receives: Diagnostic Test: Immunohistochemistry (IHC) |
| old rats | Experimental | 24-month-old rats (N=10) were employed as aged models. Immunohistochemistry (IHC) with anti-SERCA1 or -SERCA2 and anti-MHC I or -MHCII (Table 1) antibodies for 1-2 days at 4 ◦C, then washed, and incubated with Alexa Fluor® 488 donkey anti-mouse IgG and Fluor® 594 donkey anti-goat IgG secondary Abs for 1 hour at room temperature. Double IHC was performed using (anti-SERCA1 + anti-SERCA2) and (anti-SERCA2 + anti-MHCII) combinations to check co-expression. In double IHC, the same steps were done as before with mixture of primary or secondary antibodies with same dilutions. Receives: Diagnostic Test: Immunohistochemistry (IHC) |
| Denervated rats | Active comparator | In 8-12 weeks, aged rats, the larynx was approached through a midline incision using a standard operating microscope under anesthesia with sodium pentobarbital. After identification of the right recurrent and superior laryngeal nerves, a 1 cm segment was removed from the right recurrent laryngeal nerve and both ends were ligated. The right superior laryngeal nerve was also divided. The denervated rat groups were sacrificed after 2, 4, 8, and 12 weeks. The larynx was collected and prepared for IHC using the same procedure described above (n = 5 in each group).
Immunohistochemistry (IHC) with anti-SERCA1 or -SERCA2 and anti-MHC I or -MHCII (Table 1) antibodies for 1-2 days at 4 ◦C, then washed, and incubated with Alexa Fluor® 488 donkey anti-mouse IgG and Fluor® 594 donkey anti-goat IgG secondary Abs for 1 hour at room temperature. Double IHC was performed using (anti-SERCA1 + anti-SERCA2) and (anti-SERCA2 + anti-MHCII) combinations to check co-expression. In double IHC. Receives: Diagnostic Test: Immunohistochemistry (IHC) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Immuno-localization of SERCA and MHC isoform
Immuno-localization of SERCA and MHC isoform (SERCA1, SERCA2, MHC I, and MHCII) expression and co-expression in the five ILMs
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Feb 2025
- Study start25 Jan 2024
- Primary completion25 Jan 2025
- Study completion1 Feb 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for MyopathyStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- In this study, male adult Wistar rats (Shimizu Laboratory Supplies Co., Kyoto, Japan), 8-12 weeks of age, weighing 280-350 g (N=10) were used as young rats. In addition, 24-month-old rats (N=10) were employed as aged models. In 8-12 weeks, aged rats, the larynx was approached through a midline incision using a standard operating microscope under anesthesia with sodium pentobarbital. After identification of the right recurrent and superior laryngeal nerves, a 1 cm segment was removed from the right recurrent laryngeal nerve and both ends were ligated. The right superior laryngeal nerve was also divided. The denervated rat groups were sacrificed after 2, 4, 8, and 12 weeks. The larynx was collected and prepared for IHC using the same procedure described above (n = 5 in each group).
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohammed Elrabie Ahmed, Sohag University
- Investigators
- Mohammed E Ahmed, Study director, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06837467
- Sponsor's protocol ID
- sohag-5-24-2023-01
- Status last verified
- Feb 2025
- First submitted
- 7 Feb 2025
- Last updated
- 20 Feb 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Mao VH, Abaza M, Spiegel JR, Mandel S, Hawkshaw M, Heuer RJ, Sataloff RT. Laryngeal myasthenia gravis: report of 40 cases. J Voice. 2001 Mar;15(1):122-30. doi: 10.1016/S0892-1997(01)00012-1.
PubMed 12269627Marques MJ, Ferretti R, Vomero VU, Minatel E, Neto HS. Intrinsic laryngeal muscles are spared from myonecrosis in the mdx mouse model of Duchenne muscular dystrophy. Muscle Nerve. 2007 Mar;35(3):349-53. doi: 10.1002/mus.20697.
PubMed 17143878
Study at a glance
From the registry record, last updated by the sponsor on 20 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Differential Expression of SERCA and Myosin Heavy Chain Isoforms in Rat Laryngeal Muscles
- ClinicalTrials.gov ID
- NCT06837467
- Acronym / sponsor ID
- sohag-5-24-2023-01
- Conditions
- Myopathy
- Keywords
- SERCA and MHC isoform
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 25 Jan 2024 (actual)
- Primary completion
- 25 Jan 2025 (actual)
- Study completion
- 1 Feb 2025 (actual)
- First posted
- 20 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Immuno-localization of SERCA and MHC isoform (SERCA1, SERCA2, MHC I, and MHCII) expression and co-expression in the five ILMs were investigated in both young and aged rats with immunohistochemistry. Special concern has been placed to the denervation effect on ILMS.
Detailed description
Animals In this study, male adult Wistar rats (Shimizu Laboratory Supplies Co., Kyoto, Japan), 8-12 weeks of age, weighing 280-350 g (N=10) were used as young rats. In addition, 24-month-old rats (N=10) were employed as aged models.
Animal tissue preparation Animals were anesthetized with an intraperitoneal injection of sodium pentobarbital (dose 30-60 mg/kg) and were fixed with 4% paraformaldehyde following cardiac perfusion with 0.01 M phosphate-buffered saline (PBS). The larynges were excised immediately and immersed in the same fixative for approximately 12 hours at (4°C). Tissues were processed in paraffin and sectioned using a microtome (8-10 μm thickness).
The intrinsic laryngeal muscles studied were: 1) medial and lateral thyroarytenoid (MTA, LTA), (2) lateral cricoarytenoid (LCA), (3) Superior cricoarytenoid (SCA), (4) posterior cricoarytenoid (PCA), and (5) cricothyroid (CT).
Immunohistochemistry (IHC) The investigators faced unsuccessful fast fiber type identification on frozen sections then we shifted to paraffin sections. Deparaffinized sections were incubated with 3% H2O2 in PBS for 10 minutes followed by microwave treatment (5 minutes ×3 times at 500 Watt in citrate buffer, pH 6). Then, sections were incubated in a blocking solution (0.3 M glycine, 50 mM ammonium chloride, and 1% BSA in PBS) for 30 minutes before incubation in primary antibodies. Sections were incubated with anti-SERCA1 or -SERCA2 and anti-MHC I or -MHCII (Table 1) antibodies for 1-2 days at 4 ◦C, then washed, and incubated with Alexa Fluor® 488 donkey anti-mouse IgG and Fluor® 594 donkey anti-goat IgG secondary Abs for 1 hour at room temperature. Double IHC was performed using (anti-SERCA1 + anti-SERCA2) and (anti-SERCA2 + anti-MHCII) combinations to check co-expression. In double IHC, the same steps were done with a mixture of primary or secondary antibodies with the same dilutions.
Immunostained tissue sections were examined using a FV-1000 laser confocal microscope (Olympus, Tokyo, Japan). ImageJ 1.46 software was used to manually count and calculate the percentage of positive cells for each antibody.
Immunohistochemistry for denervated rat In 8-12 weeks, aged rats, the larynx was approached through a midline incision using a standard operating microscope under anesthesia with sodium pentobarbital. After identification of the right recurrent and superior laryngeal nerves, a 1 cm segment was removed from the right recurrent laryngeal nerve and both ends were ligated. The right superior laryngeal nerve was also divided. The denervated rat groups were sacrificed after 2, 4, 8, and 12 weeks. The larynx was collected and prepared for IHC using the same procedure described above (n = 5 in each group).
MHC subtypes using multi-color fiber typing:
At the beginning of our research, we tried the frozen section. After trials of several techniques to decrease autofluorescence and background noise, the investigators failed to have good staining. Then, the investigators discontinued MHC subtyping and shifted to paraffin-embedded blocks Statistical analysis The relative SERCA and MHC composition for each muscle was calculated. The available data for the positive cell percentage of each rat antibody were statistically analyzed using SPSS statistical software, version 16. Statistical comparisons were performed using the unpaired two-tailed Student's t-test and were considered significant at P < 0.05.
One-way analysis of variance (ANOVA) followed by Scheffe's post hoc test was performed to compare the MHC and SERCA composition for each muscle in denervation with the contralateral side and young with age. Values presented are means ± SD (standard deviation), with SD being across rats.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 3
- Model description
- In this study, male adult Wistar rats (Shimizu Laboratory Supplies Co., Kyoto, Japan), 8-12 weeks of age, weighing 280-350 g (N=10) were used as young rats. In addition, 24-month-old rats (N=10) were employed as aged models. In 8-12 weeks, aged rats, the larynx was approached through a midline incision using a standard operating microscope under anesthesia with sodium pentobarbital. After identification of the right recurrent and superior laryngeal nerves, a 1 cm segment was removed from the right recurrent laryngeal nerve and both ends were ligated. The right superior laryngeal nerve was also divided. The denervated rat groups were sacrificed after 2, 4, 8, and 12 weeks. The larynx was collected and prepared for IHC using the same procedure described above (n = 5 in each group).
| Arm | Type | Receives |
|---|---|---|
| Young rat | Experimental | Diagnostic Test: Immunohistochemistry (IHC)male adult Wistar rats (Shimizu Laboratory Supplies Co., Kyoto, Japan), 8-12 weeks of age, weighing 280-350 g (N=10) were used as young rats Immunohistochemistry (IHC) with anti-SERCA1 or -SERCA2 and anti-MHC I or -MHCII (Table 1) antibodies for 1-2 days at 4 ◦C, then washed and incubated with Alexa Fluor® 488 donkey anti-mouse IgG and Fluor® 594 donkey anti-goat IgG secondary Abs for 1 hour at room temperature. Double IHC was performed using (anti-SERCA1 + anti-SERCA2) and (anti-SERCA2 + anti-MHCII) combinations to check co-expression. In double IHC, the same steps were done as before with mixture of primary or secondary antibodies with same dilutions. |
| old rats | Experimental | Diagnostic Test: Immunohistochemistry (IHC)24-month-old rats (N=10) were employed as aged models. Immunohistochemistry (IHC) with anti-SERCA1 or -SERCA2 and anti-MHC I or -MHCII (Table 1) antibodies for 1-2 days at 4 ◦C, then washed, and incubated with Alexa Fluor® 488 donkey anti-mouse IgG and Fluor® 594 donkey anti-goat IgG secondary Abs for 1 hour at room temperature. Double IHC was performed using (anti-SERCA1 + anti-SERCA2) and (anti-SERCA2 + anti-MHCII) combinations to check co-expression. In double IHC, the same steps were done as before with mixture of primary or secondary antibodies with same dilutions. |
| Denervated rats | Active comparator | Diagnostic Test: Immunohistochemistry (IHC)In 8-12 weeks, aged rats, the larynx was approached through a midline incision using a standard operating microscope under anesthesia with sodium pentobarbital. After identification of the right recurrent and superior laryngeal nerves, a 1 cm segment was removed from the right recurrent laryngeal nerve and both ends were ligated. The right superior laryngeal nerve was also divided. The denervated rat groups were sacrificed after 2, 4, 8, and 12 weeks. The larynx was collected and prepared for IHC using the same procedure described above (n = 5 in each group). Immunohistochemistry (IHC) with anti-SERCA1 or -SERCA2 and anti-MHC I or -MHCII (Table 1) antibodies for 1-2 days at 4 ◦C, then washed, and incubated with Alexa Fluor® 488 donkey anti-mouse IgG and Fluor® 594 donkey anti-goat IgG secondary Abs for 1 hour at room temperature. Double IHC was performed using (anti-SERCA1 + anti-SERCA2) and (anti-SERCA2 + anti-MHCII) combinations to check co-expression. In double IHC. |
Who may qualify
- Ages
- 8 to 24 weeks
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (1 listed)
- 8-12 weeks of age, weighing 280-350 g (N=10) were used as young rats. In addition, 24-month-old rats (N=10) were employed as aged models.
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Immunohistochemistry (IHC)We faced unsuccessful fast fiber type's identification on frozen sections then we shifted to paraffin sections. Deparaffinized sections were incubated with 3% H2O2 in PBS for 10 minutes followed by microwave treatment (5 minutes ×3 times at 500 Watt in citrate buffer, pH 6). Then, sections were incubated in blocking solution (0.3 M glycine, 50 mM ammonium chloride, and 1% BSA in PBS) for 30 minutes before incubation in primary antibodies. Sections were incubated with anti-SERCA1 or -SERCA2 and anti-MHC I or -MHCII (Table 1) antibodies for 1-2 days at 4 ◦C, then washed, and incubated with Alexa Fluor® 488 donkey anti-mouse IgG and Fluor® 594 donkey anti-goat IgG secondary Abs for 1 hour at room temperature. Double IHC was performed using (anti-SERCA1 + anti-SERCA2) and (anti-SERCA2 + anti-MHCII) combinations to check co-expression. In double IHC, the same steps were done as before with mixture of primary or secondary antibodies with same dilutions. | Diagnostic test | Denervated rats, Young rat, old rats |
Primary outcome
Immuno-localization of SERCA and MHC isoform
Time frame: 6 months
Immuno-localization of SERCA and MHC isoform (SERCA1, SERCA2, MHC I, and MHCII) expression and co-expression in the five ILMs
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Feb 2025.
- Background: PubMed 12269627Mao VH, Abaza M, Spiegel JR, Mandel S, Hawkshaw M, Heuer RJ, Sataloff RT. Laryngeal myasthenia gravis: report of 40 cases. J Voice. 2001 Mar;15(1):122-30. doi: 10.1016/S0892-1997(01)00012-1.
- Background: PubMed 17143878Marques MJ, Ferretti R, Vomero VU, Minatel E, Neto HS. Intrinsic laryngeal muscles are spared from myonecrosis in the mdx mouse model of Duchenne muscular dystrophy. Muscle Nerve. 2007 Mar;35(3):349-53. doi: 10.1002/mus.20697.
- Individual participant dataSharing planned: No
Related trials for Myopathy
Not yet recruitingObservational study
Investigation of Obsessive-Compulsive Disorder in Patients With Elbow Epicondylitis
Lateral Epicondylitis, Medial Epicondylitis
RecruitingObservational study
Natural History of Inflammatory Muscle Diseases
Inflammation In Skeletal Muscle
RecruitingPhase 2
FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)
Dermatomyositis (DM), Juvenile Dermatomyositis (JDM)
Recruiting
Light Bulb Stimuli to Reduce Chronic Pain
Fibromyalgia, Musculoskeletal Pain
Not yet recruitingObservational study
From Blast Injury to Multicompartment Dysfunction:
Compartment Syndrome, Compartment Syndrome Nontraumatic Lower Extremity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mohammed E Ahmed study director
Sohag University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Immunohistochemistry (IHC) in people with Myopathy, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Immuno-localization of SERCA and MHC isoform (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06837467, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Feb 2025.